Harbin Medisan Pharmaceutical Co., Ltd.

Symbol: 002900.SZ

SHZ

10.31

CNY

Market price today

  • 62.4601

    P/E Ratio

  • 1.8348

    PEG Ratio

  • 3.19B

    MRK Cap

  • 0.01%

    DIV Yield

Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.58%

Operating Profit Margin

0.03%

Net Profit Margin

0.05%

Return on Assets

0.01%

Return on Equity

0.03%

Return on Capital Employed

0.01%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Jian Fei Qin
Full-time employees:1721
City:Harbin
Address:Limin Development Zone
IPO:2017-09-25
CIK:

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical pharmaceutical dosage forms and APIs in China. It offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, body fluid balance infusion, and other medical fields. The company was founded in 1996 and is based in Harbin, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.582% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.026%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.049%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.015% return, is a testament to Harbin Medisan Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Harbin Medisan Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.025%. Furthermore, the proficiency of Harbin Medisan Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable 0.012% return on capital employed.

Stock Prices

Harbin Medisan Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $10.26, while its low point bottomed out at $10.04. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Harbin Medisan Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 002900.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 135.98% gauges short-term asset coverage for liabilities. The quick ratio (107.85%) assesses immediate liquidity, while the cash ratio (92.54%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio135.98%
Quick Ratio107.85%
Cash Ratio92.54%

Profitability Ratios

002900.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 4.63% underscores its earnings before tax deductions. The effective tax rate stands at 15.83%, revealing its tax efficiency. The net income per EBT, 105.85%, and the EBT per EBIT, 176.15%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 2.63%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin4.63%
Effective Tax Rate15.83%
Net Income per EBT105.85%
EBT per EBIT176.15%
EBIT per Revenue2.63%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.36, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 1283.30% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding108
Days of Inventory Outstanding187
Operating Cycle215.37
Days of Payables Outstanding103
Cash Conversion Cycle113
Receivables Turnover12.83
Payables Turnover3.56
Inventory Turnover1.95
Fixed Asset Turnover0.98
Asset Turnover0.30

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.06, and free cash flow per share, -1.02, depict cash generation on a per-share basis. The cash per share value, 3.66, showcases liquidity position. A payout ratio of 0.79 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -0.02, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.06
Free Cash Flow per Share-1.02
Cash per Share3.66
Payout Ratio0.79
Operating Cash Flow Sales Ratio-0.02
Free Cash Flow to Operating Cash Flow Ratio16.47
Cash Flow Coverage Ratio-0.02
Short Term Coverage Ratio-0.02
Capital Expenditure Coverage Ratio-0.06
Dividend Paid and Capex Coverage Ratio-0.06
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 26.75%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.45, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.68%, and total debt to capitalization, 30.95%, ratios shed light on its capital structure. An interest coverage of 1.18 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio26.75%
Debt Equity Ratio0.45
Long Term Debt to Capitalization3.68%
Total Debt to Capitalization30.95%
Interest Coverage1.18
Cash Flow to Debt Ratio-0.02
Company Equity Multiplier1.68

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 3.87, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.24, reflects the portion of profit attributed to each share. The book value per share, 6.97, represents the net asset value distributed per share, while the tangible book value per share, 6.53, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share3.87
Net Income Per Share0.24
Book Value Per Share6.97
Tangible Book Value Per Share6.53
Shareholders Equity Per Share6.97
Interest Debt Per Share2.42
Capex Per Share-0.98

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 15.40%, indicates top-line expansion, while the gross profit growth, 7.18%, reveals profitability trends. EBIT growth, 37.19%, and operating income growth, 37.19%, offer insights into operational profitability progression. The net income growth, 143.86%, showcases bottom-line expansion, and the EPS growth, 151.57%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth15.40%
Gross Profit Growth7.18%
EBIT Growth37.19%
Operating Income Growth37.19%
Net Income Growth143.86%
EPS Growth151.57%
EPS Diluted Growth151.57%
Weighted Average Shares Growth-3.05%
Weighted Average Shares Diluted Growth-3.05%
Dividends per Share Growth-61.28%
Operating Cash Flow Growth-75.32%
Free Cash Flow Growth-576.18%
10-Year Revenue Growth per Share43.86%
5-Year Revenue Growth per Share-43.65%
3-Year Revenue Growth per Share-10.54%
10-Year Operating CF Growth per Share-84.43%
5-Year Operating CF Growth per Share-87.41%
3-Year Operating CF Growth per Share899.32%
10-Year Net Income Growth per Share-48.58%
5-Year Net Income Growth per Share-63.08%
3-Year Net Income Growth per Share153.53%
10-Year Shareholders Equity Growth per Share327.24%
5-Year Shareholders Equity Growth per Share13.38%
3-Year Shareholders Equity Growth per Share21.69%
10-Year Dividend per Share Growth per Share-28.72%
5-Year Dividend per Share Growth per Share-60.61%
3-Year Dividend per Share Growth per Share-56.76%
Receivables Growth-8.22%
Inventory Growth29.55%
Asset Growth5.07%
Book Value per Share Growth8.20%
Debt Growth9.39%
R&D Expense Growth26.37%
SGA Expenses Growth-4.44%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,916,803,642.85, captures the company's total value, considering both debt and equity. Income quality, 0.51, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.03, gauges operational efficiency, while the research and development to revenue, 9.51%, highlights investment in innovation. The ratio of intangibles to total assets, 4.14%, indicates the value of non-physical assets, and capex to operating cash flow, -839.31%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value3,916,803,642.85
Income Quality0.51
Sales General and Administrative to Revenue0.03
Research and Development to Revenue9.51%
Intangibles to Total Assets4.14%
Capex to Operating Cash Flow-839.31%
Capex to Revenue-25.24%
Capex to Depreciation-275.66%
Graham Number6.14
Return on Tangible Assets2.23%
Graham Net Net-0.09
Working Capital591,404,667
Tangible Asset Value2,005,675,803
Net Current Asset Value141,678,964
Average Receivables157,311,919.5
Average Payables151,485,954.5
Average Inventory184,973,632
Days Sales Outstanding46
Days Payables Outstanding140
Days of Inventory On Hand160
ROIC2.38%
ROE0.03%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.54, and the price to book ratio, 1.54, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.99, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -10.07, and price to operating cash flows, -169.49, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.54
Price to Book Ratio1.54
Price to Sales Ratio2.99
Price Cash Flow Ratio-169.49
Price Earnings to Growth Ratio1.83
Enterprise Value Multiple47.48
Price Fair Value1.54
Price to Operating Cash Flow Ratio-169.49
Price to Free Cash Flows Ratio-10.07
Price to Tangible Book Ratio1.96
Enterprise Value to Sales3.30
Enterprise Value Over EBITDA19.73
EV to Operating Cash Flow109.73
Earnings Yield1.76%
Free Cash Flow Yield-6.30%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 62.460 in 2024.

What is the ticker symbol of Harbin Medisan Pharmaceutical Co., Ltd. stock?

The ticker symbol of Harbin Medisan Pharmaceutical Co., Ltd. stock is 002900.SZ.

What is company IPO date?

IPO date of Harbin Medisan Pharmaceutical Co., Ltd. is 2017-09-25.

What is company current share price?

Current share price is 10.310 CNY.

What is stock market cap today?

The market cap of stock today is 3192541163.000.

What is PEG ratio in 2024?

The current 1.835 is 1.835 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1721.